Leukemia - search results
If you're not happy with the results, please do another search
UVA Team Targets MLL Gene Fusion in Acute Myeloid Leukemia
A team at the University of Virginia School of Medicine is leading an effort to create new therapeutic options for acute myeloid leukemia targeting a fusion protein involving the MLL protein fused with other proteins.
Immunotherapy Substantially Improves Outcomes for Babies with Leukemia
Researchers led by a team from the Netherlands have shown that adding the immunotherapy blinatumomab to chemotherapy delays progression and improves survival for infants with an aggressive type of acute lymphoblastic leukemia.
New BET- and GSK-3-Inhibitor Combo May Work against Stubborn Leukemia Subtype
A novel combination therapy may treat a leukemia subtype harboring rearrangements in the KMT2A gene, which is more common in infants. The combination uses BET- and GSK3-inhibitors.
Stems Cells Implicated in Long-Term Health Effects for Leukemia Survivors
New findings have shown that contrary to previous belief, stems cells remain in the bone marrow in acute lymphocytic leukemia. The findings provide an explanation for why survivors experience negative effects on blood formation decades after they have been cured.
Promising Menin Inhibitor Results from Leukemia Trial Published
Syndax’s revumenib shows promise in advanced acute leukemias with KMT2A rearrangements or mutant NPM1, according to findings published this week in Nature.
Children with Leukemia Living on Texas-Mexico Border More Likely to Die than Those Elsewhere...
Children with acute lymphoblastic leukemia (ALL) who lived along the Texas border with Mexico were more likely to die within five years than those living in other areas of the state.
Drug Response Study of Leukemia Subtypes Advances Precise Patient-Therapy Matching
A study by researchers at St. Jude Children’s Research Hospital delving into drug response across a swath of genetic subtypes of acute lymphoblastic leukemia (ALL), could provide a map for clinicians to more precisely match available treatments with a patient’s specific form of cancer.
Wash U Researchers Detail Key Transition Point from Chronic to Aggressive Leukemia
A key inhibiting molecule called DUSP6, plays an important role in overcoming the resistance secondary acute myeloid leukemia often develops in response to treatment with drugs called JAK2 inhibitors.
Mathematical Model Predicts Chronic Myeloid Leukemia Treatment Response
A mathematical model may predict those patients with the blood cancer chronic myeloid leukemia who will best respond to treatment with tyrosine kinase inhibitors.
Discovering the “Paradigm Shift” Associated With Chemoresistance in Acute Myeloid Leukemia
Sponsored content brought to you by ‘It was amazing to discover that AML evolution is mainly driven by methylation alterations that affect low density CpGs...